Brief: SpringWorks Therapeutics posts Q2 basic EPS USD -1.25
02/08/2023 11:44
Aug 2 (Reuters) - SpringWorks Therapeutics Q2 operating income USD -82.852 million. * Q2 basic EPS USD -1.25 * Q2 net income USD -77.925 million * Q2 operating expenses USD 82.852 million
Recent news on SpringWorks Therapeutics
See all newsBrief: Merck KGaA Completes Acquisition Of Springworks Therapeutics
Brief: Springworks Therapeutics Expects Nirogacestat Decision From European Commission In Q3
Brief: EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN